Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma-Reference-Cited by-同舟云学术

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Published:2018-06-12 Issue:10 Volume:65 Page:e27271
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Halalsheh Hadeel¹^ORCID,McCarville Mary Beth²,Neel Michael³,Reynolds Mark⁴,Cox Michael C.⁴,Pappo Alberto S.¹

Affiliation:

1. Department of Oncology; St. Jude Children's Research Hospital; Memphis Tennessee

2. Department of Diagnostic imaging; St. Jude Children's Research Hospital; Memphis Tennessee

3. Department of Surgery; St. Jude Children's Research Hospital; Memphis Tennessee

4. Loxo Oncology Inc.; South San Francisco California

Funder

Loxo Oncology, Inc.

Bayer AG

American Lebanese Syrian Associated Charities

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27271/fullpdf

Reference15 articles.

1. Congenital mesoblastic nephroma of infancy. A report of eight cases and the relationship to Wilms' tumor;Bolande;Pediatrics,1967

2. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma;Knezevich;Cancer Res,1998

3. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma;Knezevich;Nat Genet,1998

4. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion-cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma;Rubin;Am J Pathol,1998

5. ETV6-NTRK3 in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study;Vokuhl;Pediatr Blood Cancer,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers;Cancer Letters;2024-08

2. Poor outcome in congenital mesoblastic nephroma with TPM3::NTRK1 fusion: a case report from multi-disciplinary treatment to molecular tumor board;Translational Pediatrics;2024-06

3. Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?;Cancers;2024-02-28

4. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib;Acta Pharmaceutica Sinica B;2024-02

5. Safety of current treatment options for NTRK fusion-positive cancers;Expert Opinion on Drug Safety;2023-10-31